What is the cabergoline dosage for men?

Tablet strengths and labelled schedules
LabelStartStepMaximum
US label (Teva)0.25 mg orally twice weekly10.25 mg orally twice weekly, at intervals of no less than 4 weeks11 mg orally, twice weekly1
UK SmPC (Dostinex)0.5 mg per week, in one or two doses2Adding 0.5 mg per week, preferably at monthly intervals2Not above 3mg per day; doses up to 4.5 mg per week have been used in hyperprolactinaemic patients2

For hyperprolactinemic disorders in adults, the US label starts cabergoline at 0.25 mg orally twice weekly, raised by 0.25 mg orally twice weekly at intervals of no less than 4 weeks, to a maximum of 1 mg orally, twice weekly.1

Tablet strengths and labelled schedules

The table is set at the top of the page

Both labels list one tablet strength, 0.5 mg.12 The US label's dose is for adults with hyperprolactinemic disorders, idiopathic or due to pituitary adenomas, and no other use is labelled.1 The UK SmPC gives a usual dose of 1 mg per week, within a range of 0.25 mg to 2 mg per week.2 It adds that if persistent or severe adverse events occur, a temporary dose reduction followed by a more gradual increase, for example increments of 0.25 mg/week every two weeks, may increase tolerability.2

What trials in men used

No randomised trial of cabergoline dose in men turned up in searches of PubMed and trial registries; the studies below are a single-dose study in healthy men, an open longitudinal study3 and a retrospective cohort4.

TrialDose and schedulePeopleLength
Andreotti, 1995Single oral doses of 0.5, 1.0 and 1.5 mg, 5-week washouts512 healthy men5Single doses
De Rosa, 2004Dose not stated in the saved study text351 men with hyperprolactinemia, 51 healthy controls36 months3
Rudman, 2025 (retrospective)Started at a weekly dose of 0.5 mg, adjusted every 3 to 6 months447 men with microprolactinoma4Median follow-up 7.1 years4

In Andreotti 1995, all three single doses (0.5, 1.0 and 1.5 mg) produced complete prolactin suppression (below 1.0 micrograms/L) in all 12 healthy men.5 In De Rosa 2004, prolactin normalised in 74.5% of the 51 men after 6 months: 73.2% of those with macroprolactinomas and 80% of those with microprolactinomas.3 In Rudman 2025, 89.4% of the 47 men reached normal prolactin within a median 4.0 months of treatment; the other 10.6% did not.4

Healthy men and cycles

No label or human trial of cabergoline dosing for bodybuilding or on-cycle use in healthy men turned up in searches of DailyMed, the SmPC, PubMed and trial registries, and none gives a cycle length. One registry entry, NCT07568574 (an estimated 60 adult participants), lists cabergoline as an ancillary oral tablet "administered as required", gives no dose, and reports no result.6

How long treatment lasts and stopping

Neither the US label nor the UK SmPC gives a treatment length. The US label says the durability of efficacy beyond 24 months has not been established, and to monitor prolactin periodically if the tablets are stopped.1 The UK SmPC says hyperprolactinaemia usually recurs after withdrawal, though prolactin has stayed suppressed for several months in some patients.2 In Rudman 2025, withdrawal was done after at least 24 months of treatment, in men whose prolactin had normalised on low doses (0.25 mg/week).4 Thirteen men tried stopping, and only 5 stayed at normal prolactin.4

Taking, storing and safety

The US label says the tablets are given by mouth with or without food, and the UK SmPC says preferably with meals.12 The US label says to store the tablets at 20° to 25°C (68° to 77°F), and to dispense them in the original container.1 The UK SmPC gives a 2-year shelf life, not above 25 C, in a tightly closed bottle to protect from moisture.2 Neither label gives stability data for split tablets. The US label says to evaluate for valvular heart disease, including with an echocardiogram, before starting and not to give the tablets if valvular disease is detected, and to consider reducing the dose or stopping if new gambling, sexual or spending urges develop.1 It says postmarketing cases of cardiac valvulopathy have generally occurred at high doses (>2 mg/day) in Parkinson's disease, a use the label does not approve, and that cases have also been reported at lower doses in hyperprolactinemic disorders.1 Prolactin is checked by the health care provider about every 4 weeks at first, and periodically after that, according to the US label's patient information.1

Frequently asked questions

Is 0.25 mg half a tablet?

In its hyperprolactinaemia dosing, the UK SmPC gives the 0.5 mg weekly starting dose in one or two doses, two doses each being one-half of one 0.5 mg tablet; the US label describes its 0.5 mg tablets as scored.12

What do Milligram users log for cabergoline?

No cabergoline dose or schedule was logged by enough people to print a share.

References

  1. Teva Pharmaceuticals USA (DailyMed). These highlights do not include all the information needed to use CABERGOLINE TABLETS safely and effectively. See full prescribing information for CABERGOLINE TABLETS. CABERGOLINE tablets, for oral use Initial U.S. Approval: 1996. 2025. dailymed.nlm.nih.gov
  2. Pfizer Limited (emc). Dostinex Tablets - Summary of Product Characteristics (SmPC) - (emc) | 1691. medicines.org.uk
  3. PubMed. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. 2004. pubmed.ncbi.nlm.nih.gov
  4. PubMed Central. Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study. 2025. pmc.ncbi.nlm.nih.gov
  5. PubMed. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. 1995. pubmed.ncbi.nlm.nih.gov
  6. ClinicalTrials.gov. NCT07568574: Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes. 2033. clinicaltrials.gov